Ayala Pharmaceuticals, Inc. (ADXS)
(Delayed Data from OTC)
$0.02 USD
-0.08 (-80.20%)
Updated Sep 23, 2024 10:08 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Ayala Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 3 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 3 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 36 | 0 | 20 | 22 | 27 |
Income After Depreciation & Amortization | -36 | 0 | -19 | -19 | -26 |
Non-Operating Income | -16 | 0 | 5 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -52 | 0 | -14 | -18 | -26 |
Income Taxes | -4 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -48 | 0 | -14 | -18 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -48 | 0 | -14 | -18 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -36 | 0 | -19 | -18 | -24 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 1 | 3 |
Income After Depreciation & Amortization | -36 | 0 | -19 | -19 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 6.02 | NA | 1.61 | 0.76 | 0.19 |
Diluted EPS Before Non-Recurring Items | -7.99 | NA | -11.20 | -34.40 | -87.20 |
Diluted Net EPS (GAAP) | -7.99 | NA | -8.46 | -11.20 | -34.40 |
Fiscal Year end for Ayala Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 0.00 | 0.00 | 0.01 |
Cost Of Goods | NA | NA | 0.00 | 0.00 | 0.01 |
Gross Profit | NA | NA | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 8.78 | 7.13 | 8.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -8.78 | -7.13 | -8.48 |
Non-Operating Income | NA | NA | -15.79 | -0.14 | -0.09 |
Interest Expense | NA | NA | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | NA | -24.57 | -7.27 | -8.57 |
Income Taxes | NA | NA | 0.10 | 0.07 | 0.13 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | -24.67 | -7.34 | -8.70 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -24.67 | -7.34 | -8.70 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 6.02 | 4.79 | 4.78 |
Diluted EPS Before Non-Recurring Items | NA | NA | -2.96 | -1.53 | -1.82 |
Diluted Net EPS (GAAP) | NA | NA | -2.97 | -1.53 | -1.82 |